Hepatitis B Surface Antigen Decline during Sofosbuvir and Ribavirin Therapy in Hepatitis B Inactive Carriers Who Were Co-infected with Hepatitis C

Direct-acting antiviral (DAA) therapy carries a potential risk of inducing hepatitis B virus (HBV) reactivation. However, the HBV kinetics during and after DAA therapy in patients co-infected with hepatitis C virus (HCV) and HBV remain unknown. We retrospectively evaluated the HBV kinetics during an...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Shunsuke, Tsuzura, Hironori, Kita, Yuji, Ikeda, Yuji, Kabemura, Daishi, Sato, Sho, Amano, Nozomi, Yatagai, Noboru, Murata, Ayato, Shimada, Yuji, Genda, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666226/
https://www.ncbi.nlm.nih.gov/pubmed/33994440
http://dx.doi.org/10.2169/internalmedicine.7337-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666226/
https://www.ncbi.nlm.nih.gov/pubmed/33994440
http://dx.doi.org/10.2169/internalmedicine.7337-21

Ejemplares similares